NO139640C - Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner - Google Patents

Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner

Info

Publication number
NO139640C
NO139640C NO2059/73A NO205973A NO139640C NO 139640 C NO139640 C NO 139640C NO 2059/73 A NO2059/73 A NO 2059/73A NO 205973 A NO205973 A NO 205973A NO 139640 C NO139640 C NO 139640C
Authority
NO
Norway
Prior art keywords
16alfa
dioxypregna
dioner
17alfa
alkyliden
Prior art date
Application number
NO2059/73A
Other languages
English (en)
Other versions
NO139640B (no
Inventor
Ralph Lennart Brattsand
Karl Goeran Claeson
Bo Thureson Af Ekenstam
Bror Arne Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO139640(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of NO139640B publication Critical patent/NO139640B/no
Publication of NO139640C publication Critical patent/NO139640C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO2059/73A 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner NO139640C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (no) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
NO139640B NO139640B (no) 1979-01-08
NO139640C true NO139640C (no) 1979-04-18

Family

ID=20269234

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2059/73A NO139640C (no) 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Country Status (26)

Country Link
US (2) US3929768A (no)
JP (1) JPS5521760B2 (no)
AT (1) AT328630B (no)
BE (1) BE799727A (no)
CA (1) CA1002938A (no)
CH (1) CH595400A5 (no)
CS (1) CS178129B2 (no)
CY (1) CY1013A (no)
DD (1) DD104295A5 (no)
DE (1) DE2323215C3 (no)
DK (1) DK134783B (no)
ES (1) ES414673A1 (no)
FI (1) FI50631C (no)
FR (1) FR2185405B1 (no)
GB (1) GB1429922A (no)
HK (1) HK49179A (no)
HU (1) HU166680B (no)
IL (1) IL42155A (no)
KE (1) KE2970A (no)
NL (2) NL177493C (no)
NO (2) NO139640C (no)
PL (1) PL87765B1 (no)
SE (1) SE378109B (no)
SU (1) SU470954A3 (no)
YU (1) YU35896B (no)
ZA (1) ZA732955B (no)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
PL309402A1 (en) * 1992-12-24 1995-10-02 Rhone Poulenc Rorer Ltd Novel steroides
DK0678097T3 (da) * 1993-01-08 2000-02-07 Astra Ab Hidtil ukendte colon- eller ileumspecifikke steroidderivater
HU220868B1 (en) 1993-04-02 2002-06-29 Byk Gulden Lomberg Chem Fab New prednisolone derivative, process for its production, use of the same and pharmaceutical composition containing the same
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2561315A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
EP1869064A2 (en) * 2005-11-02 2007-12-26 Sicor, Inc. Improved process for the preparation of ciclesonide
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
KR101467590B1 (ko) 2006-08-22 2014-12-01 랜박시 래보러터리스 리미티드 매트릭스 메탈로프로테나제 저해제
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2626067A1 (en) 2006-12-26 2013-08-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
RS51780B (sr) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
ATE545417T1 (de) 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
US8796248B2 (en) 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
US20100331539A1 (en) * 2008-03-13 2010-12-30 Farmabios S.P.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
DK3403654T3 (da) 2009-10-01 2019-08-26 Adare Dev I L P Oralt administrerede kortikosteroidsammensætninger
UA109417C2 (uk) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2755648B1 (en) 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
RU2698197C2 (ru) 2012-08-24 2019-08-23 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Гетероциклические модуляторы активности hif для лечения заболеваний
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
BR112015022784B1 (pt) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc Método de condicionamento de material cristalino micronizado e sistemas de condicionamento
BR112015028964A2 (pt) 2013-05-22 2017-07-25 Pearl Therapeutics Inc composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
MY199937A (en) 2016-11-08 2023-11-29 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12070506B2 (en) 2018-01-08 2024-08-27 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP2024525567A (ja) 2021-07-09 2024-07-12 アストラゼネカ・ファーマシューティカルズ・リミテッド・パートナーシップ エアロゾル薬物送達のための組成物、方法および系
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
JP2025511436A (ja) 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
JP2025523332A (ja) 2022-10-25 2025-07-23 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来ａｄｃリンカー－ペイロード、医薬組成物、及びそれの使用
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (no) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
ZA732955B (en) 1974-04-24
CY1013A (en) 1979-11-23
HK49179A (en) 1979-07-27
JPS4941378A (no) 1974-04-18
NL177493B (nl) 1985-05-01
DK134783C (no) 1977-06-06
PL87765B1 (no) 1976-07-31
GB1429922A (en) 1976-03-31
CH595400A5 (no) 1978-02-15
NO139640B (no) 1979-01-08
NL177493C (nl) 1985-10-01
SE378109B (no) 1975-08-18
IL42155A (en) 1977-06-30
ATA436573A (de) 1975-06-15
NL930025I1 (nl) 1993-06-01
DK134783B (da) 1977-01-17
BE799727A (fr) 1973-09-17
HU166680B (no) 1975-05-28
YU35896B (en) 1981-08-31
FI50631C (fi) 1976-05-10
ES414673A1 (es) 1976-07-01
CA1002938A (en) 1977-01-04
CS178129B2 (no) 1977-08-31
NO1994013I1 (no) 1994-08-31
AU5525373A (en) 1974-11-07
AT328630B (de) 1976-03-25
JPS5521760B2 (no) 1980-06-12
DE2323215C3 (de) 1978-03-30
FR2185405B1 (no) 1976-12-31
NL7306978A (no) 1973-11-21
YU129173A (en) 1981-02-28
KE2970A (en) 1979-07-20
US3929768A (en) 1975-12-30
IL42155A0 (en) 1973-07-30
US3983233A (en) 1976-09-28
FR2185405A1 (no) 1974-01-04
SU470954A3 (ru) 1975-05-15
DE2323215A1 (de) 1973-11-29
DE2323215B2 (de) 1977-08-11
FI50631B (no) 1976-02-02
DD104295A5 (no) 1974-03-05

Similar Documents

Publication Publication Date Title
NO139640C (no) Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
SE414771B (sv) Forfarande for framstellning av nya 11,11-alkyliden-steroider
SE7505040L (sv) Forfarande for framstellning av n-fosfonometylglycin.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
NO143460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO141800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
SE390819B (sv) Analogiforfarande for framstellning av piperazinyl-propyl-1,2,4-triazolinderivat
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO142173C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme, 1,1-diaryl-1-oksadiazolalkylaminderivater
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
DK136534C (da) Analogifremgangsmade til fremstilling af d-homopregna-1,4-dien-3,20-dioner
SE7504842L (sv) Forfarande for framstellning av adeninderivat..
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
NO139088C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2beta,16beta-diamino-5alfa-androstaner
NO144928C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive zantinderivater.
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
SE397827B (sv) Forfarande for framstellning av 1-aminometyl-2,2-difenylcyklopropankarboxamidderivat med terapeutisk verkan
SE400768B (sv) Forfarande for framstellning av 2-fenyl-6-sulfamoyl-7-klor-1,2,3,4-tetrahydro-4-kinazolinon
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE399557B (sv) Forfarande for framstellning av tiantren-, tioxanten- och fenoxatiinderivat
NO138568C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 21-(bea-benzoylaminoisobutyryl)-16alfa,17alfa-(p-dimethyl-aminobenzyliden)-triamcinolon
SE400767B (sv) Forfarande for framstellning av arylpiperazin-derivat av adenin